Spravato’s Drug Classification: How Esketamine Works

image showing headshot of Dr.-Aaron-Brown
Medical Director, Board-Certified Psychiatrist (DO)

Dr. Aaron Brown is NeuroGlow’s Medical Director and a highly accomplished, board certified Psychiatrist with over a decade of experience. He reviews NeuroGlow’s clinical content and oversees its treatment protocols.

Table of Content

A therapist supports a distressed woman during a calm consultation about Spravato Drug Class and treatment options.

Medically reviewed by Dr. Aaron Brown, DO, Medical Director and Board-Certified Psychiatrist · Last reviewed June 2026.

Spravato is the brand name for esketamine nasal spray, a prescription treatment used for certain adults with depression. Its main drug class is NMDA receptor antagonist, and it is also classified as a Schedule III controlled substance in the United States. That classification can sound concerning, but it does not mean Spravato is illegal or automatically unsafe. It means Spravato has accepted medical use, while also carrying risks that require careful medical control. These risks include sedation, dissociation, abuse, misuse, and dependence. For patients and families, the key point is simple. Spravato is not a typical take-home antidepressant. It is a supervised medical treatment that should be discussed with a qualified provider who can review the patient’s diagnosis, treatment history, medical risks, and safety needs.

What drug class is Spravato?

Spravato is in a drug class called NMDA receptor antagonists. Its active ingredient is esketamine, which is the S-enantiomer of ketamine. The FDA prescribing information describes Spravato as a non-competitive N-methyl-D-aspartate, NMDA, receptor antagonist. This means Spravato works through a different brain pathway than many common antidepressants. Many oral antidepressants, such as SSRIs and SNRIs, mainly affect serotonin or norepinephrine. Spravato is different because it acts on the brain’s glutamate system. The exact way esketamine produces its antidepressant effect is not fully known, but its NMDA receptor activity is central to its classification. Spravato was first approved by the FDA in 2019 for adults with treatment-resistant depression. In January 2025, the treatment-resistant depression indication was updated so Spravato may be used by itself or with an oral antidepressant.

What does Schedule III mean for Spravato?

Medical professional holding a Spravato esketamine nasal spray device inside a clinic.

Schedule III means Spravato has accepted medical use in the United States, but it also has enough abuse or dependence risk to require stricter controls. The DEA classifies controlled substances based on accepted medical use and potential for abuse or dependence. Schedule III medications have lower abuse potential than Schedule I or II substances, but more abuse potential than Schedule IV substances. For Spravato patients, Schedule III status mainly affects how treatment is handled. Spravato is not picked up from a retail pharmacy and used at home. It is administered in a healthcare setting, and patients are monitored after each treatment session.

 

Schedule III point What it means for Spravato patients
Accepted medical use Spravato is FDA-approved for specific adult depression indications
Abuse and misuse risk Providers must assess risk before and during treatment
Extra controls Spravato is handled differently from routine prescriptions
No home use Patients do not take Spravato home
Post-dose monitoring Patients are observed after treatment before leaving

Schedule III does not mean Spravato is automatically unsafe. It means Spravato must be used with the right screening, supervision, and follow-up.

Why is Spravato a Schedule III controlled substance?

Spravato is a Schedule III controlled substance because it contains esketamine, which is related to ketamine. Esketamine can affect mood, perception, alertness, and judgment. Because of these effects, the FDA classifies Spravato as esketamine nasal spray, CIII. CIII means Schedule III. This classification does not mean Spravato has no medical value. It means the opposite: Spravato has accepted medical use, but it also has risks if it is used incorrectly. These risks include misuse, abuse, and dependence. That is why Spravato is handled with more care than many standard antidepressants. The main reason for this extra control is how Spravato can affect a person shortly after treatment. Some patients may feel sleepy, disconnected from their surroundings, lightheaded, or mentally slowed down. Because these effects can happen, Spravato is given in a medical setting instead of being sent home like a regular prescription. So, Spravato is Schedule III because it has both approved medical use and controlled substance risks. The goal is not to make treatment harder for patients. The goal is to make sure Spravato is used safely, correctly, and under the right medical supervision.

Does Schedule III mean Spravato is unsafe?

A side-by-side infographic explaining the safety and regulation of the medication Spravato under Schedule III classification.

No. Schedule III does not mean Spravato is unsafe. It means Spravato has accepted medical use, but it also has risks that require controlled access and medical oversight. For Spravato, the main concerns are what can happen if the medication is used incorrectly or without proper monitoring. Spravato can cause sedation, dissociation, respiratory depression, blood pressure increases, impaired judgment, and impaired coordination. The FDA label also states that Spravato may be subject to abuse and diversion. A better way to understand Schedule III is this: it is a controlled-substance classification, not a statement that Spravato has no medical value. For the right patient, Spravato can be a legitimate treatment option. It just should not be treated like a casual or routine medication.

Is Spravato considered an antidepressant?

Yes, Spravato is considered an antidepressant treatment because it is FDA-approved for certain adults with depression. The FDA first approved Spravato in 2019 for adults with treatment-resistant depression. The current prescribing information lists Spravato for treatment-resistant depression in adults, either by itself or with an oral antidepressant. It is also approved for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior, when used with an oral antidepressant. Still, Spravato is not the same as common antidepressants like SSRIs or SNRIs. Those medications usually focus on serotonin or norepinephrine. Spravato works differently because it is an NMDA receptor antagonist. This means it acts on a different brain pathway connected to glutamate signaling. The FDA label identifies esketamine as a non-competitive NMDA receptor antagonist. So the clearest way to say it is this: Spravato is an antidepressant treatment by use, but an NMDA receptor antagonist by drug class.

What is Spravato FDA-approved to treat?

A detailed infographic split into two main sections illustrating the FDA-approved uses for Spravato (esketamine) nasal spray.

Spravato is FDA-approved for specific adult depression indications. It is not approved for every person with depression. The current FDA prescribing information lists Spravato for treatment-resistant depression in adults, either by itself or with an oral antidepressant. It is also approved for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior, when used with an oral antidepressant. Spravato’s treatment-resistant depression indication changed in January 2025. Before that update, Spravato was used for treatment-resistant depression with an oral antidepressant. The current label allows Spravato to be used as monotherapy or with an oral antidepressant for adults with treatment-resistant depression. It is also important to be precise about suicide-related language. Spravato is not proven to prevent suicide or reduce suicidal thoughts or behaviors. It also does not replace hospitalization when emergency care is needed. If someone may harm themselves or someone else, call 911 or 988 in the United States, or go to the nearest emergency room.

What is an NMDA receptor antagonist?

An NMDA receptor antagonist is a medication that blocks or changes activity at NMDA receptors in the brain. NMDA stands for N-methyl-D-aspartate. These receptors are part of the glutamate system, which helps brain cells communicate. Spravato is classified this way because its active ingredient, esketamine, acts on NMDA receptors. The FDA label describes esketamine as a non-selective, non-competitive NMDA receptor antagonist. This is one reason Spravato is different from many traditional antidepressants. SSRIs and SNRIs mainly affect serotonin or norepinephrine. Spravato works through a different system, although the exact antidepressant mechanism is still not fully known.

Does Spravato have abuse or misuse risk?

Patient reviews Spravato drug class safety information with a therapist in a supervised clinical setting

Yes. Spravato has a risk of abuse and misuse. This is one reason it is classified as a Schedule III controlled substance. The FDA label says Spravato contains esketamine and “may be subject to abuse and diversion.” It also says providers should assess each patient’s risk before prescribing it and continue watching for signs of abuse or misuse during treatment. Abuse and misuse are not exactly the same thing:

  • Misuse means using Spravato in a way other than prescribed.
  • Abuse means using it for nonmedical effects, such as intoxication or altered perception.
  • Dependence means the body or brain has adapted to a substance, which can create problems if use changes or stops.
  • Addiction usually refers to compulsive use despite harm. A provider should evaluate this risk based on the patient’s history.

This risk does not mean every patient will have a problem with Spravato. It means the risk is real enough that patients need proper screening and monitoring. People with a history of drug abuse, alcohol misuse, or substance dependence may have a higher risk. Janssen MedicalConnect notes that careful consideration is advised before treatment in people with a history of substance use disorder, including alcohol use disorder. Spravato can be helpful for the right patient, but it should be taken seriously. Patients should tell their provider about any past or current substance use, even if it feels uncomfortable. That information helps the provider decide whether Spravato is appropriate and how to manage treatment safely.

Can Spravato be taken at home?

No. Spravato cannot be taken at home. It must be taken in a certified healthcare setting while a healthcare provider is present. The official Spravato REMS site states that Spravato “must never be dispensed directly to a patient for home use.” This is different from many regular prescriptions. A patient does not pick up Spravato from a retail pharmacy, take it home, and use it alone. Even though Spravato is a nasal spray, it is still a controlled medication with effects that need supervision. During treatment, the patient uses the nasal spray under direct observation. After that, they stay at the treatment center for monitoring for at least 2 hours. This is done because Spravato can cause side effects like sleepiness, dissociation, dizziness, blood pressure changes, or breathing problems. Patients also should not drive, operate machinery, or do anything that requires full alertness until the next day after a restful sleep. The official patient experience guide gives the same instruction because Spravato can affect mental alertness and coordination after treatment. Spravato is not an at-home depression medication. It is a supervised treatment that must be given in the right medical setting.

Who can prescribe or administer Spravato?

Patient using Spravato nasal spray during supervised treatment with a therapist in a clinical setting

Spravato can only be prescribed and given through a certified medical setting. It is not a regular prescription that a patient picks up from a pharmacy and uses alone. A qualified healthcare provider must evaluate whether Spravato is appropriate. This usually involves reviewing the patient’s depression history, past treatments, medical conditions, blood pressure, medication list, and any substance use concerns. Spravato is different because the patient takes the nasal spray under the direct observation of a healthcare provider. The official Spravato REMS site states that Spravato is intended for use only in a certified healthcare setting, and patients must be monitored by a healthcare provider for at least 2 hours after administration. In practical terms, this means Spravato treatment may involve:

  • A prescribing clinician who determines whether Spravato is appropriate
  • A certified treatment setting where Spravato can be administered
  • A healthcare provider who observes the dose
  • Post-treatment monitoring before the patient leaves
  • Clear instructions about transportation and safety after the visit

Spravato should only be prescribed and administered by trained medical professionals in a setting that is certified to provide it. This protects patients because Spravato can cause sedation, dissociation, blood pressure changes, and other effects that need supervision. The FDA label also states that patients should be monitored for at least 2 hours after administration because of risks such as sedation, dissociation, and respiratory depression.

What should patients with substance use history know before Spravato?

Patient discussing Spravato treatment options with a therapist during a clinical consultation

Patients with a history of substance use should be open with their provider before starting Spravato. This includes past or current use of alcohol, prescription medications, recreational drugs, or any history of dependence. This does not always mean Spravato is automatically off the table. It means the provider needs to look more carefully at the risks and benefits. The FDA label says people with a history of drug abuse or dependence may have a greater risk of abuse and misuse with Spravato. It also says providers should assess each patient’s risk before prescribing and monitor for concerning behaviors during treatment. Patients should tell their provider if they have:

  • A history of substance use disorder
  • Past alcohol misuse or alcohol use disorder
  • Past misuse of prescription medications
  • Current cravings or relapse concerns
  • A history of drug-seeking behavior
  • Concerns about feeling “high,” detached, or out of control during treatment

substance use history should be part of the Spravato conversation, not something patients hide. Being honest helps the provider decide whether Spravato is appropriate and what safety steps are needed.

What should patients ask before starting Spravato?

Before starting Spravato, patients should ask clear questions about safety, eligibility, treatment setting, and what the full treatment process looks like. Good questions include:

  • Do I meet the criteria for treatment-resistant depression?
  • Why are you recommending Spravato for my situation?
  • Will I take Spravato by itself or with an oral antidepressant?
  • What side effects should I expect during and after treatment?
  • How will my blood pressure be checked before and after each session?
  • How will you monitor me for sedation, dissociation, or breathing changes?
  • Do I need someone to drive me home after each visit?
  • When can I safely drive or return to normal activities?
  • How does my substance use history affect my risk?
  • What signs of misuse or dependence should I watch for?
  • How long is the treatment plan, and when will we review progress?
  • What are the costs, insurance steps, and financial support options?

These questions matter because Spravato is not a routine medication. The FDA label says patients should be monitored for at least 2 hours after each dose because of risks such as sedation, dissociation, and respiratory depression. It also says providers should assess abuse and misuse risk before prescribing Spravato. Patients should also ask practical questions before the first appointment. Spravato can affect alertness and coordination, so patients should not drive or operate machinery until the next day after restful sleep. The official Spravato discussion guide also encourages patients to ask how Spravato is administered, where treatment happens, and whether financial support is available. NeuroGlow offers a professional, closely supervised path for patients considering Spravato treatment for depression. Since Spravato is an esketamine nasal spray classified as an NMDA receptor antagonist and a Schedule III controlled substance, treatment requires careful evaluation, certified administration and post-treatment monitoring. NeuroGlow helps patients better understand whether Spravato is appropriate for their condition, what safety steps are involved and how this treatment differs from traditional antidepressants used at home.

FAQs

Is Spravato a narcotic?

No. Spravato is not best described as a narcotic. Its active ingredient is esketamine, and its drug class is NMDA receptor antagonist. It is also a Schedule III controlled substance, which is why people sometimes confuse the terms.

Is Spravato the same as ketamine?

No. Spravato is related to ketamine, but it is not the same as standard ketamine treatment. Spravato contains esketamine, which is one part of ketamine, and it is an FDA-approved nasal spray for specific depression indications.

Is Spravato addictive?

Spravato has a risk of abuse, misuse, and dependence. That does not mean every patient will become addicted. It means providers must take the risk seriously, especially for people with a history of substance use.

Can I drive after Spravato treatment?

No. Patients should not drive, operate machinery, or do anything that requires full alertness until the next day after a restful sleep. This warning appears in the official prescribing information and patient guidance.

Why do patients need to stay after Spravato treatment?

Patients are monitored after treatment because Spravato can cause effects such as sedation, dissociation, dizziness, blood pressure changes, and breathing-related problems. Official Spravato safety guidance requires monitoring for at least 2 hours after administration.

Can Spravato be picked up at a pharmacy?

No. Spravato is not dispensed directly to patients for home use. It must be used in a certified healthcare setting under medical supervision.

Does Spravato work for everyone with depression?

No. Spravato is not for everyone with depression. It is approved for specific adult depression indications, including treatment-resistant depression. A qualified provider must decide whether it fits a patient’s diagnosis, treatment history, medical risks, and safety needs.

Does Spravato prevent suicide?

No. Spravato is approved for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior, when used with an oral antidepressant. However, it is not proven to prevent suicide or reduce suicidal thoughts or behaviors, and it does not replace hospitalization when emergency care is needed.

What is the main thing to remember about Spravato’s drug class?

Spravato is an esketamine nasal spray. Its drug class is NMDA receptor antagonist, and it is classified as a Schedule III controlled substance in the United States. That means it has accepted medical use, but it also requires careful medical control.

References:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf

https://www.jnj.com/media-center/press-releases/janssen-announces-u-s-fda-approval-of-spravatotm-esketamine-ciii-nasal-spray-for-adults-with-treatment-resistant-depression-trd-who-have-cycled-through-multiple-treatments-without-relief

Considering treatment? Learn more about Spravato treatment in DFW at NeuroGlow, or book a free consultation with our team.

Considering Spravato in DFW? NeuroGlow bills BCBS of Texas, Aetna, Cigna, UnitedHealthcare, Humana, Medicare, Texas Medicaid (prior authorization required), TRICARE (administered in Texas by TriWest) and VA Community Care for Spravato at REMS-certified clinics in Fort Worth, McKinney and Flower Mound (coverage facts verified by our billing team on October 28, 2026). See if Spravato is right for you or call 469-218-4410.

Share This Article:

Find more of NeuroGlow's mental health education on Google.

Add us as a preferred source and Google will show you more of our articles in your own search results. It is your choice and you can change it any time in your Google settings.

Or add NeuroGlow on Google's preferred sources page

Portrait of Trevor J. Bidstrup, MA, LPC, LMHC, specialized mental health counselor and expert in Ketamine Assisted Psychotherapy (KAP).
Licensed Professional Counselor (LPC, LMHC)

Trevor J. Bidstrup, MA, LPC, LMHC, is a licensed professional counselor and licensed mental health counselor who focuses on Ketamine Assisted Psychotherapy (KAP). He has served as a KAP Director and holds roles in ASKP3 and the Professional Psychedelic Providers Association.

Contact Us

Our expert team is eager to embark on this journey with you, providing personalized and compassionate care that exceeds your expectations.

Related Posts

man taking spravato and seems spravato addictive

Is Spravato Addictive? Facts You Need to Know

Key Takeaways Esketamine is a Schedule III medicine with abuse and misuse risk, which…

Read More
Older adult reviewing Medicare Advantage coverage for Spravato with a NeuroGlow care coordinator in Dallas-Fort Worth

Does Medicare Advantage cover Spravato? Plans NeuroGlow accepts in DFW

Aetna Medicare, BCBS TX Medicare, Cigna Medicare, Humana Medicare, UHC/Optum Medicare and Wellcare are…
Read More
Spravato patient at NeuroGlow

7 Top-Rated Spravato Clinics in Flower Mound, North Texas

Medically reviewed by Dr. Aaron Brown, DO, Medical Director and Board-Certified Psychiatrist · Last…

Read More
Scroll to Top

Book a Free Consultation!

Fill out the form below for a FREE consultation or inquiries about our treatments. (Your information will remain confidential and won’t be shared without consent.)